B3GNT9 and glioblastoma: Further exploration of the relationship between β3GNT9 and clinically relevant indicators of glioblastoma suggested that patients older than 65 years of age had higher β3GNT9 expression than patients of or under 65 years of age (P<0.05, Figure 2B).